Vanessa, in partnership with her colleague, Dr. Anderson, served as the U.S. D&I leads for the Employee Resource Group (ERG) Capitol Hill Fly-In. They worked to produce content, align with ERG associates for the opportunity and partnered with Public Affairs to execute the initiative. The Fly-in provided Novartis associates who participate in ERGs with an

Dr. Anderson, in partnership with her colleague, Vanessa Adams, served as the U.S. D&I leads for the Employee Resource Group (ERG) Capitol Hill Fly-In. They worked to produce content, align with ERG associates for the opportunity and partnered with Public Affairs to execute the initiative. The Fly-in provided Novartis associates who participate in ERGs with

With years of experience in both pharmaceuticals and digital medicine, Rohit is driving Otsuka’s launch strategy to bring prescription digital therapeutics to patients suffering from serious mental illness. His work has propelled Otsuka as a driver of legislation around creating a benefit category and reimbursement paradigm for PDTs.

Over the years, Dr. Chureen Carter has demonstrated her commitment to supporting and mentoring rising scientists. In her work building alliances that support evidence generation, Dr. Carter puts patients first, ensuring stakeholders understand the full value of the medicines they need. She has an exceptional ability to build bridges, whether with partners outside the organization

A self-described “number monkey,” Doug’s work in data modeling has been an essential component of Merck’s legislative strategy. Doug is committed to ensuring the government affairs team is always equipped with data to guide and advance their advocacy efforts. His recent work on drug pricing reform echoes his ability to supply complex guidance in a

In 2020, Dr. Dent was a key voice in discussing the importance of biomarkers for Alzheimer’s disease with members of Congress. She participated in Capitol Hill briefings and attended multiple meetings with legislators to explain the issue. She is a powerful advocate for pioneering innovation and continues to be a trusted advisor and partner to

As a specialist in cell therapy, Victoria has played a vital role in engaging policymakers at every level of government including state and federal “fly-ins” hosted by PhRMA. BMS’s Policy, Government Affairs, and Advocacy team is continually impressed by her thoughtful approach to educating and advocating for medical innovation, like CAR T.

Kim is an individual who is committed to helping educate policymakers and stakeholders about the important and challenging work of developing new medicines for patients. She participates in several fly-ins and she’s UCB’s leading voice on the importance of diversity in clinical trials and is leading work to advance the company in this area. Her

Formerly an R&D scientist, her passion for improving the public health system led her to pivot to public policy and advocacy. Kate is now focused on elevating the role of vaccines in the broader health care debate. Her recent work includes the launch of a website called “Vaccine Track” — a searchable database that allows

Lori’s work to educate her colleagues on policy developments and the value of our industry helps create enthusiasm among her colleagues when Astellas asks for voluntary engagement on legislation. She also empowers women across the company as a passionate member of the Stellar Women Employee Impact Group.